Iovance Biotherapeutics for a new wave of TIL (Tumor-Infiltrating Lymphocyte) cancer therapies.

An early-stage Kite Pharma (now Gilead Oncology), but focused on TIL (Tumor-Infiltrating Lymphocyte) cell therapy for cancer.

• ITIL-168: An autologous tumor-infiltrating lymphocyte (TIL) cell therapy product candidate being developed for various solid tumors, including melanoma and non-small cell lung cancer.
• ITIL-306: A TIL cell therapy product candidate designed to target folate receptor alpha (FOLR1) for indications such as gynecological cancers and non-small cell lung cancer.

Instil Bio, Inc. (TIL) is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. As a clinical-stage company, its primary activities involve research and development, and conducting clinical trials for its product candidates (ITIL-168, ITIL-306).

Therefore, Instil Bio does not currently have any major commercial customers, as its therapies are still in development and have not yet received regulatory approval for sale to hospitals, clinics, or individual patients.

Bronson Crouch, Chief Executive Officer and Chairman

Mr. Crouch is an entrepreneur and investor with over 15 years of experience in the biotechnology and pharmaceutical industry. He is currently the Managing Partner of Curative Ventures, a private equity investment firm focused on biopharma opportunities. His past involvement includes CoStim Pharmaceuticals, Inc. (acquired by Novartis in 2014) and Peloton Therapeutics, Inc. (acquired by Merck in 2019 for $1.1 Billion cash upfront), demonstrating a pattern of managing companies that were subsequently sold to acquirers and managing companies backed by private equity firms.

Sandeep “Steve” Laumas, MD, Chief Financial Officer & Chief Business Officer

Dr. Laumas has served as the Chief Financial Officer and Chief Business Officer of Instil Bio since February 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in healthcare investment banking before transitioning to healthcare equity research. He was an analyst at Balyasny Asset Management from 2001-03 and a Managing Director of North Sound Capital from 2003-07, where he managed the global healthcare investment portfolio. Dr. Laumas founded and managed Bearing Circle Capital, an investment partnership, since 2008. He also served as a board member, Executive Chairman, and CEO of 9 Meters Biopharma, Inc.

Jamie Freedman, MD, PhD, Chief Medical Officer

Dr. Freedman brings over 20 years of experience in the pharmaceutical and biotech industries, having held executive positions in senior R&D, Commercial, and Medical leadership roles at major companies such as Merck, GSK, Medimmune/AZ, and Genentech/Roche. His career has led to 15 drug approvals and successful launches across various therapeutic areas.

Mark E. Dudley, PhD, Chief Scientific Officer

Dr. Dudley was previously the Chief Scientific Officer. He was involved in the founding of Immetacyte as a cell therapy spinout from the University of Manchester and served as a Cancer Research UK Professor of Medical Oncology at the University of Manchester and Christie Hospital.

The key risks to Instil Bio's business operations include:

1. Failure of Product Candidates and Pipeline Attrition: As a clinical-stage biopharmaceutical company, Instil Bio's success is heavily dependent on the successful development and regulatory approval of its product candidates. The company has faced significant setbacks, including the discontinuation of its lead unmodified tumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, due to manufacturing issues and a strategic reprioritization. Although ITIL-306 (a CoStAR-TIL therapy) had its trial resumed after a pause related to manufacturing analysis, there has been a lack of recent positive clinical data, and the company initially shifted its focus towards a bispecific antibody program, AXN-2510/IMM2510. However, Instil Bio has also recently terminated the licenses for AXN-2510 and AXN-27M, discontinuing their development as well. This series of pipeline failures and strategic pivots, including the discontinuation of its most advanced programs, presents a critical risk to the company's future viability and potential for commercial products.
2. Manufacturing Challenges for Cell Therapies: Instil Bio develops autologous (patient-derived) cell therapies, such as TILs, which involve highly complex, patient-specific manufacturing processes that are expensive, prone to logistical issues, and difficult to scale. The company previously experienced a decrease in the rate of successful manufacturing for ITIL-168, leading to a voluntary pause in clinical trials and an inability to dose some patients. While corrective actions were implemented for ITIL-306, the inherent manufacturing complexity for cell and gene therapies remains a significant and ongoing risk, impacting the ability to consistently produce viable treatment products for clinical trials and, ultimately, for commercialization.
3. High Cash Burn Rate and Need for Additional Capital: As a clinical-stage biopharmaceutical company with no revenue, Instil Bio incurs substantial research and development (R&D) expenses and costs associated with clinical trials and manufacturing scale-up. The company's financial health is characterized by zero revenue and significant losses. Despite efforts to reduce operating expenses through workforce reductions, the core weakness remains the high cash burn required to advance its pipeline. While management has made projections about its cash runway, the need for substantial additional capital raises is likely required sooner than anticipated to fund clinical development, especially given the recent discontinuation of key pipeline programs.

The clear emerging threat to Instil Bio is the advancement and potential widespread commercialization of **allogeneic (off-the-shelf) cell therapies for cancer.**

Instil Bio specializes in autologous tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting a patient's own tumor cells, expanding them in a lab, and reinfusing them. This process is highly personalized, complex, time-consuming, and expensive. Allogeneic cell therapies, in contrast, aim to create universal, "off-the-shelf" immune cell products that can be manufactured in advance and administered to multiple patients, bypassing the logistical and cost challenges of autologous treatments.

If allogeneic cell therapies, particularly those using gene-edited T-cells, NK cells, or induced pluripotent stem cell (iPSC)-derived immune cells, demonstrate comparable or superior efficacy and safety while offering significant advantages in terms of accessibility, manufacturing scalability, and cost, they could fundamentally disrupt the market for autologous cell therapies like Instil Bio's TILs. This would be analogous to Netflix (scalable, on-demand content) threatening Blockbuster (physical, limited inventory) by offering a more convenient and potentially cost-effective alternative to a similar core service.